1.A Novel Cytosolic Isoform of Mitochondrial Trans-2-Enoyl-CoA Reductase Enhances Peroxisome Proliferator-Activated Receptor alpha Activity.
Dong Gyu KIM ; Jae Cheal YOO ; Eunju KIM ; Young Sun LEE ; Oleg V YARISHKIN ; Da Yong LEE ; Kun Ho LEE ; Seong Geun HONG ; Eun Mi HWANG ; Jae Yong PARK
Endocrinology and Metabolism 2014;29(2):185-194
BACKGROUND: Mitochondrial trans-2-enoyl-CoA reductase (MECR) is involved in mitochondrial synthesis of fatty acids and is highly expressed in mitochondria. MECR is also known as nuclear receptor binding factor-1, which was originally reported with yeast two-hybrid screening as a binding protein of the nuclear hormone receptor peroxisome proliferator-activated receptor alpha (PPARalpha). However, MECR and PPARalpha are localized at different compartment, mitochondria, and the nucleus, respectively. Therefore, the presence of a cytosolic or nuclear isoform of MECR is necessary for functional interaction between MECR and PPARalpha. METHODS: To identify the expression pattern of MECR and the cytosolic form of MECR (cMECR), we performed reverse transcription polymerase chain reaction (RT-PCR) with various tissue samples from Sprague-Dawley rats. To confirm the interaction between cMECR and PPARalpha, we performed several binding assays such as yeast two-hybrid, coimmunoprecipitation, and bimolecular fluorescence complementation. To observe subcellular localization of these proteins, immunocytochemistry was performed. A luciferase assay was used to measure PPARalpha activity. RESULTS: We provide evidence of an alternatively spliced variant of the rat MECR gene that yields cMECR. The cMECR lacks the N-terminal 76 amino acids of MECR and shows uniform distribution in the cytoplasm and nucleus of HeLa cells. cMECR directly bound PPARalpha in the nucleus and increased PPARalpha-dependent luciferase activity in HeLa cells. CONCLUSION: We found the cytosolic form of MECR (cMECR) was expressed in the cytosolic and/or nuclear region, directly binds with PPARalpha, and enhances PPARalpha activity.
Alternative Splicing
;
Amino Acids
;
Animals
;
Carrier Proteins
;
Complement System Proteins
;
Cytoplasm
;
Cytosol*
;
Fatty Acids
;
Fluorescence
;
HeLa Cells
;
Humans
;
Immunohistochemistry
;
Luciferases
;
Mass Screening
;
Mitochondria
;
Oxidoreductases*
;
Polymerase Chain Reaction
;
PPAR alpha*
;
Rats
;
Rats, Sprague-Dawley
;
Reverse Transcription
;
Yeasts
2.Diclofenac, a Non-steroidal Anti-inflammatory Drug, Inhibits L-type Ca2+ Channels in Neonatal Rat Ventricular Cardiomyocytes.
Oleg V YARISHKIN ; Eun Mi HWANG ; Donggyu KIM ; Jae Cheal YOO ; Sang Soo KANG ; Deok Ryoung KIM ; Jae Hee SHIN ; Hye Joo CHUNG ; Ho Sang JEONG ; Dawon KANG ; Jaehee HAN ; Jae Yong PARK ; Seong Geun HONG
The Korean Journal of Physiology and Pharmacology 2009;13(6):437-442
A non-steroidal anti-inflammatory drug (NSAID) has many adverse effects including cardiovascular (CV) risk. Diclofenac among the nonselective NSAIDs has the highest CV risk such as congestive heart failure, which resulted commonly from the impaired cardiac pumping due to a disrupted excitation-contraction (E-C) coupling. We investigated the effects of diclofenac on the L-type calcium channels which are essential to the E-C coupling at the level of single ventricular myocytes isolated from neonatal rat heart, using the whole-cell voltage-clamp technique. Only diclofenac of three NSAIDs, including naproxen and ibuprofen, significantly reduced inward whole cell currents. At concentrations higher than 3 micrometer, diclofenac inhibited reversibly the Na+ current and did irreversibly the L-type Ca2+ channels-mediated inward current (IC50=12.89+/-0.43 micrometer) in a dose-dependent manner. However, nifedipine, a well-known L-type channel blocker, effectively inhibited the L-type Ca2+ currents but not the Na+ current. Our finding may explain that diclofenac causes the CV risk by the inhibition of L-type Ca2+ channel, leading to the impairment of E-C coupling in cardiac myocytes.
Animals
;
Anti-Inflammatory Agents, Non-Steroidal
;
Calcium Channels, L-Type
;
Diclofenac
;
Heart
;
Heart Failure
;
Ibuprofen
;
Muscle Cells
;
Myocytes, Cardiac
;
Naproxen
;
Nifedipine
;
Patch-Clamp Techniques
;
Rats